Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Antimicrob Agents Chemother
; 61(8)2017 08.
Article
em En
| MEDLINE
| ID: mdl-28559269
ABSTRACT
Rifamycins exhibit concentration-dependent killing of Mycobacterium tuberculosis; higher exposures potentially induce better outcomes. We randomized 180 tuberculosis patients in Peru to receive rifampin at 10, 15, or 20 mg/kg/day. A total of 168 had noncompartmental pharmacokinetic analyses; 67% were sampled twice, and 33% were sampled six times. The doses administered were well tolerated. The median area under the concentration-time curve from 0 to 6 h (interquartile range) was 24.9 (17.6 to 32.1), 43.1 (30.3 to 57.5), or 55.5 (35.7 to 73.2) h · µg/ml. The median maximum drug concentration in serum in the experimental arms reached the target of 8 µg/ml. Continued investigation of higher rifampin doses is warranted. (This study has been registered at ClinicalTrials.gov under registration no. NCT01408914.).
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Rifampina
/
Tuberculose
/
Mycobacterium tuberculosis
/
Antituberculosos
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
País como assunto:
America do sul
/
Peru
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article